Journal: BMC cancer
Article Title: Histone deacetylase inhibitor panobinostat induces antitumor activity in epithelioid sarcoma and rhabdoid tumor by growth factor receptor modulation.
doi: 10.1186/s12885-021-08579-w
Figure Lengend Snippet: Fig. 2 Rhabdoid tumor is more sensitive to in vitro inhibition of growth factor receptors than epithelioid sarcoma. A Half-maximal inhibitory concentration (IC50) after 72 h, based on confluence (IncuCyte®) or MTS assay (*) in N ≥3 biological replicates. B EGFR, FGFR1 and FGFR2 mRNA expression levels of A204, VAESBJ, and GRU1 cells were determined by RT-qPCR. The scatter plot shows measurements of N ≥3 biological replicates in 3 technical replicates, normalized on GAPDH expression (dCT (cycle threshold) values; median ± IQR ). C Cell proliferation in response to EGF and FBS10% in serum-starved cells by IncuCyte®, graph represents means ± SEM of N ≥3 biological replicates. D Effects on AKT and ERK activity after treatment with pazopanib (left panel) and regorafenib (right panel) after 5, 30 and 120 min, assessed by Western blot (ratio candidate protein/β-ACTIN, related to expression of control)
Article Snippet: Cell lines and cell culture Rhabdoid tumor cell line A204 was purchased from Leibniz Institute DSMZ (German Collection of Microrganisms and Cell Cultures), epithelioid sarcoma cell line VAESBJ from ATCC® (American Type Culture Collection).
Techniques: In Vitro, Inhibition, Concentration Assay, MTS Assay, Expressing, Quantitative RT-PCR, Activity Assay, Western Blot, Control